In COVID-19 clinical update #70, Daniel Griffin discusses efficacy of portable air cleaners, vaccine induced serum neutralizing antibodies against variants, prevention and attenuation of disease with mRNA vaccines, ivermectin to prevent hospitalization, IL-6 antagonists and mortality, and impact of vaccination on long COVID.
Hosts: Daniel Griffin and Vincent Racaniello
Click arrow to play
Download TWiV 778 (22 MB .mp3, 37 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Efficacy of portable air cleaners (MMWR) 5:14
- Ad26.COV2.S elicited neutralization of variants (bioRxiv) 8:40
- Prevention of COVID-19 with mRNA vaccines (NEJM) 11:29
- Ivermectin to prevent hospitalization (BMC Inf Dis) 17:12
- IL-6 antagonists and mortality (JAMA) 20:05
- Impact of vaccination on long COVID (Lancet) 22:40
- Letters read on TWiV 778 26:53
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
The paper in BMC Inf Dis notes in terms of Ivermectin safety ‘no per protocol serious adverse events were observed during the study.’
Also the authors state during the study non-serious adverse events were evenly distributed between treatment and placebo arms.
This corresponds to the past reported minuscule
level of adverse events associated with the use of Ivermectin in humans when dosed appropriate for weight as was done in this study.